ArticlePrecision radiation oncology2025
Chemoradioimmunotherapy versus chemoimmunotherapy or chemoradiotherapy in extensive-stage small-cell lung cancer: A retrospective analysis of survival outcomes.
Article in Precision radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- Deep learning model based on automated CT image segmentation for predicting the optimal radiotherapy protocol in limited-stage small cell lung cancer patients: a multicenter study.Translational lung cancer research · 2026Article
- Adebrelimab-based regimens as first-line treatment for ES-SCLC in specific populations: a real-world study in Chinese patients.Therapeutic advances in medical oncology · 2026Article
- Chemoradioimmunotherapy versus chemoimmunotherapy or chemoradiotherapy in extensive-stage small-cell lung cancer: A retrospective analysis of survival outcomes.Precision radiation oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Current evidence is insufficient to define the value of thoracic radiotherapy (TRT) following chemoimmunotherapy (CT-IO) in extensive-stage small-cell lung cancer (ES-SCLC). We aimed to ascertain whether incorporating immunotherapy (IO) could improve survival and explore the efficacy of TRT in combination with CT-IO among patients with ES-SCLC. Methods: Clinical data were retrospectively analyzed. Patients were classified into two groups: IO and chemoradiotherapy (CRT). Within the IO group, we further defined two subgroups: CT-IO and chemoradioimmunotherapy (CRT-IO) groups. Results: A total of 206 patients were enrolled in this study. The median overall survival was 22.2 months in the CRT-IO group, which was longer than the 16.0 months observed in the CT-IO group ( Conclusions: Considering the trend toward prolonged survival and a higher ORR in the CRT-IO group, TRT may be feasible in IO era. Considering the economic factors and physical conditions, CRT may be an option for patients with ES-SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.